VeChain, Renji Hospital and DNV GL Held Strategic Partnership Signing Ceremony To Launch World’s First Blockchain Intelligent Tumor Treatment Center

SHANGHAI, Oct. 27, 2020 /PRNewswire/ — In partnership with VeChain and DNV GL, Renji Hospital, a top-ranked hospital in China affiliated with the Shanghai Jiaotong University School of Medicine, has announced the launch of the world’s first blockchain-enabled Intelligent Tumor Treatment Center on October 20, 2020. The Intelligent Tumor Treatment Center is a transparent, efficient, and traceable medical management solution powered by VeChain ToolChainTM.

Sunny Lu, Co-founder and CEO of VeChain & Jidong Zhang, Vice President of Renji Hospital & George Kang, Senior Vice President of DNV GL Group
Sunny Lu, Co-founder and CEO of VeChain & Jidong Zhang, Vice President of Renji Hospital & George Kang, Senior Vice President of DNV GL Group

As strategic partners of this new initiative, VeChain and DNV GL will jointly support the hospital in the quest to improve global public health through state-of-the-art blockchain technology and professional advisory.

VeChain ToolChainTM Powers The World’s First Intelligent Tumor Treatment Center 

The Intelligent Tumor Treatment Center combines the advantages of VeChain blockchain technology with DNV GL’s professional services. It enables full patient ownership of personal medical records, allowing patients to take control of the authorization and medical records data management. Research institutions inside and outside the hospital can use authorized data to improve the efficiency of clinical research, and regulatory agencies can use authorized data to conduct business compliance checks on medical institutions and establish a credit evaluation system.

Zhang Jidong, Vice President of Renji Hospital, said, “The launch of the Intelligent Tumor Treatment Centre intends to enhance high-quality integrated development of Renji Hospital. Moving forward, Renji intends to boost our healthcare facilities with more blockchain-powered use cases and projects, which will be gradually disclosed together with our partners when the time is right.”

George Kang, Senior Vice President of DNV GL Group, said, “Through independent and objective medical evaluation methods, DNV GL intends to provide more services for Renji Hospital to improve its service quality and medical experience, moving to a new stage of higher standards, higher requirements and higher quality.”

Sunny Lu, co-founder and CEO of VeChain, said, “As digital transformation accelerates in the healthcare sector, VeChain will continue to demonstrate its advantages and flexibility as a superior blockchain platform that is suitable for all types of use cases and industries. We are very proud and excited to be contributing to the public health industry by providing the technology for Renji Hospital’s Intelligent Tumor Treatment Centre.”

VeChain Facilitating Digital Transformation To Improve Public Health

In line with the Chinese Government’s 14th Five-Year (2021-2025) Plan for Economic and Social Development, the National Health Commission formulated an official guideline and re-emphasized blockchain technology as an essential innovation and integration of the medical and health industry. VeChain is committed to solving the pain points of digital medical reform through blockchain technology and balancing personal privacy and public interests.

By using the self-developed one-stop data BaaS platform VeChain ToolChainTM , we have many proven cases in the medical sector, including a blockchain powered Clinical Trial Traceability Platform for Bayer China, and a blockchain-enabled medical data management platform named The E-NewHealthLife

Read more

Pandemic may be making it harder for pregnant women who use opioids to get effective treatment

Opioid use in pregnancy has prompted new guidance from the American Academy of Pediatrics aimed at improving care for women and for newborns affected by their mothers’ drug use.

The number of affected women and infants has increased in recent years but they often don’t get effective treatment, and the coronavirus pandemic may be worsening that problem, said Dr. Stephen Patrick, lead author of the academy report released Monday.

“While we have been talking about the opioid crisis for years, pregnant women and their newborns seldom make it to the top of the heap. Infants are receiving variable care and not getting connected to services,” said Patrick, a Vanderbilt University pediatrician.

The academy’s report says pregnant women should have access to opioid medication to treat opioid misuse. Two opioids, buprenorphine and methadone, are effective treatments but pregnant women often face stigma in using them and doctors who prescribe them are scarce.

The academy says hospitals should have written protocols for assessing and treating opioid-affected newborns. Many don’t and practices vary widely.

Breastfeeding and other practices that promote bonding should be encouraged, and parent education and referral to services for affected newborns should be provided, the academy says. Its recommendations echo guidance from other medical groups and the U.S. government.

“This is a substantial public health problem that is still lacking solutions,” Patrick said.

According to the federal Centers for Disease Control and Prevention, 7% of U.S. women reported in 2019 that they had used prescription opioids during pregnancy. One-in-five of those women reported misusing the drugs while pregnant.

Some infants born to these women develop symptoms of opioid withdrawal, including tremors, fussiness and diarrhea.

By some U.S. estimates, nearly 80 affected infants are diagnosed every day and the numbers have tripled in recent years.

Patrick has done research suggesting that these infants may be at risk for developmental delays but says it’s possible those findings reflect use of alcohol or other drugs during pregnancy, poor prenatal care or stress.

“Getting into treatment may be getting even harder” because of the pandemic, he said. “There’s so much going on in the world that that issues involving opioid use are flying under the radar.”

Source Article

Read more

Northwestern Medicine Central DuPage Hospital offers MitraClip, an alternative treatment to open heart valve surgery

In patients with mitral regurgitation, the mitral valve does not close completely, allowing blood to flow backward or “leak” into the upper chamber of the heart, causing shortness of breath, fatigue and dizziness. The debilitating condition can lead to congestive heart failure, atrial fibrillation, pulmonary hypertension, stroke or death.

Historically, patients with severe mitral regurgitation required open heart surgery. The Bluhm Cardiovascular Institute at Northwestern Medicine Central DuPage Hospital is now offering Mitraclip, a minimally invasive procedure for patients who may not be able to tolerate surgery.



“As a national leader in transcatheter mitral valve treatment options, Northwestern Memorial Hospital has one of the highest-volume MitraClip programs in Illinois,” said Patrick McCarthy, MD, executive director of the Bluhm Cardiovascular Institute and chief of cardiac surgery at Northwestern Memorial Hospital. “By training our team at Central DuPage Hospital in Winfield, we are bringing advanced care to patients closer to where they live.”

During MitraClip implantation, a catheter is inserted through the femoral vein in the leg, up into the heart until it reaches the diseased mitral valve. The MitraClip implant is compressed and advanced along the guide wire so that it can be properly positioned to join or “clip” together a portion of the mitral valve, reducing or eliminating the backward flow of blood.

“Patients experience a noticeable difference in their symptoms and improved quality of life very quickly,” said Imran N. Ahmad, MD, interventional cardiologist and medical director of the Northwestern Medicine Central DuPage Hospital Cardiac Catheterization Laboratory. “With the less invasive procedure, patients spend only 24 to 48 hours in the hospital, compared to about five days for an open heart procedure.”

William Lenschow, of Sycamore, was the first patient to undergo the MitraClip procedure at Northwestern Medicine Central DuPage Hospital. The 84 year-old farmer was so weak from his leaking mitral valve that he found it difficult to walk. Within two weeks of the procedure, Lenschow was back at work on his farm harvesting the soybean crop.



“Before the procedure I was so tired I slept more than I ever have in my life. I could only sit around and do nothing. I’ve never lived my life that way,” said Lenschow. “After the procedure, I felt better almost immediately. It feels good to be active and working again.”

Northwestern Memorial Hospital participated in the COAPT clinical trial, which found treatment with MitraClip leads to a reduction in hospitalizations for heart failure and death compared to medical therapy alone. As a result of these findings, the FDA approved MitraClip for patients with functional or secondary mitral regurgitation caused by diminished heart function

“Mitral valve disease is one of the most common valve disorder in the United States and one of the more difficult to treat,” said Jonathan Tomasko, MD, cardiac surgeon at Northwestern Medicine Central DuPage Hospital. “MitraClip arms us with another tool in

Read more

Non-Invasive Prostate Cancer Test Boosts Early Treatment

For years, men with an elevated PSA had two options: adopt a wait-and-see approach, or, to find out with certainty whether they had cancer, get a biopsy, a painful procedure where a physician puts a needle through the wall of the rectum and into the prostate. It also carries risk of bleeding or infection.

Instead, Ripken’s urologist, Ronald Tutrone Jr., chief of the Division of Urology at the Greater Baltimore Medical Center, recommended the ExoDx Prostate Test, a newer, simple urine test that looks for genetic changes indicating prostate cancer. When that test came back elevated, Ripken went ahead with a biopsy that indeed revealed he had prostate cancer. He underwent successful surgery in March, and is now in remission.

Ripken feels fortunate his cancer was caught in the early stages, and that he was able to get the ExoDX Prostate Test. “Without it I might have decided to simply watch my PSA levels for a while, and the cancer might have spread.”

For more than thirty years, the PSA has been the gold standard when it comes to detecting prostate cancer. But it’s also had its share of controversy. “There have been concerns that a positive PSA test has led to overdiagnosis and overtreatment,” says James Wysock, M.D., a urologic oncologist and assistant professor of urology at NYU Grossman School of Medicine in New York City. In men with PSA levels in the 4.0 to 10 range, biopsy confirms cancer about 25 percent of the time. This means that the remaining 75 percent would have to undergo a procedure that’s painful, anxiety-producing, and carries risks including infection and bleeding. And even if the test successfully picks up cancer, Wysock adds, many prostate cancers grow so slowly that they will not cause harm during a man’s lifetime. But to be on the safe side, many men opt for treatment, which carries risk of side effects such as incontinence and impotence.

Now, not only can several new blood and urine tests more accurately measure your risk for prostate cancer, they can also detect how aggressive your cancer is, so that both you and your doctor can come up with a targeted treatment. “Not all prostate cancers need to be treated — we can sometimes do what’s known as active surveillance, where you’re monitored over time to see if your levels rise,” explains Wysock.

The ExoDx, which has been available since 2017, works by checking a man’s urine for specific prostate cancer biomarkers that would indicate tumor cell growth. If the test comes back with a score under 15.6, it’s considered low risk or benign. Anything higher could indicate cancer. Ripken’s score was 45.

Similar specific tests to diagnose prostate cancer have been available for close to a decade. Two of the earliest ones were the Prostate Health Index (PHI), FDA approved in 2012, and the 4Kscore test, approved in 2015. These both combine the results of different types of PSA to get an overall score that reflects the chance a man

Read more

Birth asphyxia: Causes, symptoms, and treatment

Birth asphyxia is a condition in which a baby does not receive enough oxygen before, during, or directly after birth.

In severe cases, it can cause serious complications and even be life threatening. Immediate treatment is necessary to ensure that the baby receives enough oxygen.

In this article, we look at the causes and symptoms of birth asphyxia, as well as the potential complications, treatment, and prevention.

Other names for birth asphyxia include perinatal asphyxia and neonatal asphyxia.

Birth asphyxia occurs when an infant does not receive enough oxygen when born, potentially leading to difficulty breathing. It can happen just before, during, or after birth.

Insufficient oxygen supply to the body can cause low levels of oxygen or a buildup of excess acid in the baby’s blood.

These effects can be life threatening and require immediate treatment.

In mild or moderate cases, babies may recover fully. However, in severe cases, birth asphyxia can cause permanent damage to the brain and organs or be fatal.

Birth asphyxia rates are lower in developed countries, with a rate of 2 in 1,000 births. In areas of developing countries where there is limited access to neonatal care, this rate increases up to 10 times.

A variety of factors can cause birth asphyxia. These can relate to the pregnant person or the fetus, and they include:

  • Umbilical cord prolapse: This birth complication occurs when the umbilical cord leaves the cervix before the baby.
  • Compression of the umbilical cord
  • Meconium aspiration syndrome: This syndrome occurs when a baby inhales a mixture of amniotic fluid and meconium, their first feces.
  • Premature birth: If a baby is born before 37 weeks, their lungs may not yet be fully developed, and they may be unable to breathe properly.
  • Amniotic fluid embolism: Although rare, this complication — in which amniotic fluid enters the pregnant person’s bloodstream and causes an allergic reaction — is very serious.
  • Uterine rupture: Research has shown a significant association between tears in the muscular wall of the uterus and birth asphyxia.
  • The placenta separates from the uterus: This separation can happen before the birth.
  • Infection during labor
  • Prolonged or difficult labor
  • High or low blood pressure in pregnancy
  • Anemia: In a baby with anemia, the blood cells are not carrying enough oxygen.
  • Not enough oxygen in the pregnant person’s blood: The level of oxygen may be insufficient before or during birth.

Risk factors for birth asphyxia include:

  • the pregnant person being between the ages of 20 and 25 years
  • multiple births, such as delivering twins or triplets
  • not attending prenatal care
  • low birth weight
  • abnormal position of the fetus during delivery
  • preeclampsia or eclampsia
  • history of birth asphyxia in a previous birth

Signs and symptoms of birth asphyxia can occur before, during, or just after birth. Before birth, a baby might have an abnormal fetal heart rate or low blood pH levels, which indicate excess acid.

Signs in the baby at birth can indicate a lack of oxygen or blood flow. They include:

  • unusual skin tone
Read more

Indigenous mobile health unit combines traditional and modern medicine for treatment

A mobile health unit in Toronto is combining traditional Indigenous treatments and modern medicine to help care for the city’s homeless and most vulnerable people.

Anishnawbe Health Toronto developed its mobile health unit after witnessing a rise in homelessness and overdoses brought on by the COVID-19 pandemic. The nurses, doctors and social workers tour the city’s homeless encampments and other areas to test and treat people in need of medical attention.

“We are providing COVID testing and for people that are homeless, transient and living rough, and also primary health care,” Jane Harrison with the Anishnawbe Health Toronto Mobile Unit told CTV News.

The system allows the health unit to track and care for the people who are experiencing homelessness and may have contracted COVID-19, while also affording them the ability to travel to where they’re needed most.

Now, the mobile health unit typically sees about 100 people per day.

“You can find 50 (to) 60 tents in some of these parks,” said Harvey Manning, director of Programs and Services at Anishnawbe Health Toronto. “What has happened is a lot of drop-in’s have closed. There’s fewer places for people to eat.”

Anishnawbe Health Toronto began in 1984 after its founder, Joe Sylvester, realized a “more comprehensive approach to health care” was needed among the Indigenous community in Toronto.

The health unit promotes traditional forms of Indigenous medicine and practices and offers its patients access to traditional healers, elders and medicine people, along with dentists, chiropractors and massage therapists. The health unit also helps people looking to “escape homelessness.”

“Anishnawbe Health has saved my life,” said Bonnie Gegwetch, a client of the organization.

For Gegwetch, having access to Anishnawbe Health Toronto has helped her to connect with her roots.

“I’m part of the 60s scoop,” she said. “This is my culture, this is where I found it.”

“Anishnawbe health has done an awesome job.”

The health unit is currently fundraising to put all of its services in one new building in downtown Toronto. Construction on the new facility is set to begin later this year.

Wiith files from CTV National News and Indigenous Circle reporter Donna Sound

Source Article

Read more

Remdesivir, first COVID-19 drug treatment, gets FDA approval

U.S. regulators on Thursday approved the first drug to treat COVID-19: remdesivir, an antiviral medicine given to hospitalized patients through an IV.

The drug, which California-based Gilead Sciences Inc. is calling Veklury, cut the time to recovery by five days — from 15 days to 10 on average — in a large study led by the U.S. National Institutes of Health.

It had been authorized for use on an emergency basis since spring, and now becomes the first drug to win full Food and Drug Administration approval for treating COVID-19. President Donald Trump received it when he was sickened earlier this month.

Veklury is approved for people at least 12 years old and weighing at least 88 pounds (40 kilograms) who are hospitalized for a coronavirus infection. For patients younger than 12, the FDA will still allow the drug’s use in certain cases under its previous emergency authorization.

The drug works by inhibiting a substance the virus uses to make copies of itself. Certain kidney and liver tests are required before starting patients on it to ensure it’s safe for them and to monitor for any possible side effects. And the label warns against using it with the malaria drug hydroxychloroquine, because that can curb its effectiveness.

“We now have enough knowledge and a growing set of tools to help fight COVID-19,” Gilead’s chief medical officer, Dr. Merdad Parsey, said in a statement.

The drug is either approved or has temporary authorization in about 50 countries, he noted.

Its price has been controversial, given that no studies have found it improves survival. Last week, a large study led by the World Health Organization found the drug did not help hospitalized COVID-19 patients, but that study did not include a placebo group and was less rigorous than previous ones that found a benefit. The FDA’s approval statement noted that, besides the NIH-led one, two other studies found the drug beneficial.

Gilead charges $2,340 for a typical treatment course for people covered by government health programs in the United States and other developed countries, and $3,120 for patients with private insurance. The amount that patients pay out of pocket depends on insurance, income and other factors.

So far, only steroids such as dexamethasone have been shown to cut the risk of dying of COVID-19. The FDA also has given emergency authorization to using the blood of survivors, and two companies are currently seeking similar authorization for experimental antibody drugs.

Source Article

Read more

Childhood Absence Epilepsy Treatment Market Research Report by Drug, by Disease Type – Global Forecast to 2025

Childhood Absence Epilepsy Treatment Market Research Report by Drug (Lamotrigine, Phase 2 Drugs, and Valproate), by Disease Type (Atypical Absence Seizures and Typical Absence Seizures) – Global Forecast to 2025 – Cumulative Impact of COVID-19

New York, Oct. 22, 2020 (GLOBE NEWSWIRE) — announces the release of the report “Childhood Absence Epilepsy Treatment Market Research Report by Drug, by Disease Type – Global Forecast to 2025 – Cumulative Impact of COVID-19” –

The Global Childhood Absence Epilepsy Treatment Market is expected to grow from USD 181.92 Million in 2019 to USD 263.89 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 6.39%.

Market Segmentation & Coverage:
This research report categorizes the Childhood Absence Epilepsy Treatment to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Drug, the Childhood Absence Epilepsy Treatment Market studied across Lamotrigine, Phase 2 Drugs, and Valproate.

Based on Disease Type, the Childhood Absence Epilepsy Treatment Market studied across Atypical Absence Seizures and Typical Absence Seizures.

Based on Geography, the Childhood Absence Epilepsy Treatment Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Childhood Absence Epilepsy Treatment Market including AbbVie, Cavion, Inc., GlaxoSmithKline plc, Insys Therapeutics, Pfizer Inc., Pfizer Inc., and Teva Pharmaceutical Industries Ltd..

FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Childhood Absence Epilepsy Treatment Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain,

Read more

Blood test may identify pancreatic cancers that will respond to treatment, researchers say

Oct. 22 (UPI) — Researchers have developed a simple blood test to identify pancreatic cancers that are more likely to respond to treatment than others, according to a paper published Thursday by Clinical Cancer Research.

The test detects and measures the levels of a sugar called sTRA, which is produced by some types of pancreatic cancer and escapes into the bloodstream. Pancreatic cancers that produce sTRA often do not respond to chemotherapy, the researchers said.

Testing prostate cancer patients for sTRA one day could guide treatment decisions, sparing patients with untreatable cancers from undergoing unnecessary therapies and experiencing potential side effects.

“Knowing which type of pancreatic cancer a person has is critical to implementing the right treatment strategy for each patient,” one of the researchers, Brian Haab, said in a statement.

“We hope that our new test, which detects a marker produced by cancer cells of one subtype and not the other, will one day soon be a powerful tool to help physicians and patients make the best decisions possible,” said Haab, a professor at the Van Andel Institute in Michigan.

About 60,000 people in the United States are diagnosed with pancreatic cancer annually and nearly 50,000 people die from it each year, according to the National Cancer Institute.

Pancreatic cancers are among the most challenging malignancies to treat, due in part to their ability to evade detection until they have advanced and spread.

No reliable way exists to determine whether a patient has a type of pancreatic cancer that will respond to existing chemotherapies, and the result often is a blanket treatment approach that works in some patients but can leave all with troubling side effects.

The new sTRA test evolved from an earlier test that combined an existing diagnostic approach designed to detect a sugar called CA19-9 with a new one that detected sTRA.

The combination approach detected nearly 70% of pancreatic cancers with a less than 5% false-positive rate — roughly 30% more than the CA19-9 alone, the researchers said.

Both the combination test and the new sTRA test still need to undergo further clinical studies to confirm their accuracy, they said.

“The … combination test tells us whether there is cancer, and the new sTRA test helps us determine what kind of pancreatic cancer, which then could allow physicians to better narrow down the appropriate treatment plan,” Haab said.

“When used in sequence, we believe the combination test and the new sTRA test could help catch and identify pancreatic cancer more quickly and definitively,” he said.

Source Article

Read more

Mom-Of-Four Dies At 31 After Cancer Treatment Canceled During Coronavirus Lockdown

Coronavirus pandemic has resulted in diagnoses and treatments being put on hold or delayed, resulting in the deterioration or even death of several patients. One such patient was a woman battling brain cancer who died after her chemotherapy was paused during the coronavirus lockdown in the United Kingdom.

The woman, identified as 31-year-old Emma Jenkinson, was suffering from grade 4 brain cancer, a condition she had previously beaten in her early 20s.

Her treatment was put on hold after the pandemic hit the country in March this year. Her condition deteriorated and she died earlier this month, leaving her four children and husband behind.

“She has grade four brain cancer and unfortunately her chemotherapy was paused in March due to covid19, before this, the cancer was reacting well to treatment,” her husband Andrew wrote on a GoFundMe page set up to raise funds for the woman’s family.

“At the beginning of May, Emma started feeling really unwell. She started losing her balance, falling over. At its worst she was falling 15-20 times a day. She actually fell over in the garden quite heavily and banged her head on a post so I had to rush her to A&E. It was later in the month she had a scan and found that the cancer had increased and was placed on chemotherapy straight away,” he added.

Her condition deteriorated in September.

“Unfortunately in September she started getting pressure in her head and feeling unwell again and after another scan she was told that the chemotherapy has stopped working,” he wrote.

They were then informed by the doctor that her surgery cannot be conducted as it will cause lot damage and affect her quality of life.

She died the following month. 

Calling her a “fantastic mother,” Andrew wrote, “All Emma wants like any mother is for her children to be healthy & happy in the future. All she wants is for the children to have happy memories of her and us all together.”

cancer chemo In this photo, patient receives chemotherapy treatment for breast cancer at the Antoine-Lacassagne Cancer Center in Nice on July 26, 2012. Photo: Reuters/Eric Gaillard

Source Article

Read more